oncology– tag –

Recent research highlights that aging and obesity each independently promote cancer progression and can act synergistically to worsen outcomes. Recent research highlights that aging and obesity each independently promote cancer progressi...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modaliti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, This article is the comprehensive summary of our Morningglorysciences Summer Beginner ...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Dru...

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. In this final volume, we summarize th...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa...

On August 8, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamo...

On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals), a protease activator, for adult and pediatric patients (≥1 year) with progressive H3 K27M-mutant...

In this second installment of our series on bispecific antibody drugs, we delve into the diverse structural formats that define the field. In this second installment of our series on bispecific antibody drugs, we delve into the diverse s...

Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. In recent ...

Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. Throughout this series, we have explore...

Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. This series aims to provide a clear and accessib...

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In previous installments, we've explored the fundamentals of C...

For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In pa...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. In this third installment of our introductory series on in vivo ...

Strategic Review: Investing in Marketed Products and Next-Gen Modalities Astellas Pharma has executed a series of acquisitions and collaborations from 2015 to 2025 focused on immuno-oncology, ophthalmology, neurology, and gene therapy. A...

Strategic Review: Global Expansion through ADC-Focused Oncology Partnerships Daiichi Sankyo has built a strong global presence through its antibody-drug conjugate (ADC) platform. Daiichi Sankyo has built a strong global presence through ...

Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Takeda has transformed its...

Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Regeneron Pharmaceutical...